Tobi M, Luo F C, Ronai Z
Molecular Carcinogenesis Program, American Health Foundation, Valhala, NY 10595.
J Natl Cancer Inst. 1994 Jul 6;86(13):1007-10. doi: 10.1093/jnci/86.13.1007.
K-ras gene mutation appears in more than 50% of patients with colon tumors. Both its frequency and early appearance may qualify this mutation as a potential biomarker. To enable early detection of mutant K-ras alleles, we had previously developed a sensitive polymerase chain reaction (PCR)-based assay, i.e., enriched PCR, which enables detection of one mutant K-ras allele present within 10,000 normal alleles. Using the enriched PCR, we were able to detect mutant K-ras alleles in "normal-appearing" colonic mucosa in patients with colorectal cancer.
A study was initiated to determine whether mutant K-ras alleles could be identified in colonic effluent samples of patients who may be at risk to develop colorectal cancer.
Over 9 years, colonic effluent samples were collected prior to routine colonoscopy from 39 patients who were apparently free of colorectal cancer. These samples were collected from patients with a family history of colorectal cancer (n = 7), adenomatous polyps (n = 7), previously resected colorectal cancer (n = 5), inflammatory bowel disorders (n = 13), normal colonoscopic examination (n = 6), and familial adenomatous polyposis (n = 1). All of the samples were double coded and analyzed for K-ras gene mutation.
Of the 39 patients, seven were found to harbor mutant K-ras codon 12 alleles. Mutations were found in patients with a family history of colorectal cancer (three of seven), adenomatous polyps (one of seven), previously resected colorectal carcinoma (two of five), and familial adenomatous polyposis (one of one). In one case, effluent was found to harbor a mutant K-ras allele 4 years before the patient was diagnosed with colorectal cancer.
(a) Effluent samples contain enough DNA to be detected with enriched PCR. Such samples may well be representative of the entire colon in general as opposed to a localized area such as that usually analyzed during colonoscopy. (b) K-ras gene mutation can be identified in routinely obtained colonic washings of patients who are at risk of developing colorectal cancer. Such mutations were absent in patients with inflammatory bowel disorders and in those who had undergone normal colonoscopic examinations. Detection of K-ras mutation in colonic washings may assist in identifying patients who may be at high risk for developing adenocarcinoma of the colon.
The ability to examine colonic effluents provides a powerful and convenient source of sampling and may be adapted for future large-scale screening.
超过50%的结肠肿瘤患者存在K-ras基因突变。该突变的频率及其早期出现可能使其有资格成为一种潜在的生物标志物。为了能够早期检测突变的K-ras等位基因,我们之前开发了一种基于聚合酶链反应(PCR)的灵敏检测方法,即富集PCR,它能够检测出10000个正常等位基因中存在的一个突变K-ras等位基因。使用富集PCR,我们能够在结直肠癌患者“外观正常”的结肠黏膜中检测到突变的K-ras等位基因。
开展一项研究以确定在可能有患结直肠癌风险的患者的结肠流出物样本中是否能鉴定出突变的K-ras等位基因。
在9年多的时间里,在常规结肠镜检查前从39名明显无结直肠癌的患者中收集结肠流出物样本。这些样本来自有结直肠癌家族史的患者(n = 7)、腺瘤性息肉患者(n = 7)、先前接受过结直肠癌切除术的患者(n = 5)、炎症性肠病患者(n = 13)、结肠镜检查正常的患者(n = 6)以及家族性腺瘤性息肉病患者(n = 1)。所有样本均进行双重编码并分析K-ras基因突变情况。
在这39名患者中,有7名被发现携带突变的K-ras密码子12等位基因。在有结直肠癌家族史的患者(7名中的3名)、腺瘤性息肉患者(7名中的1名)、先前接受过结直肠癌切除术的患者(5名中的2名)以及家族性腺瘤性息肉病患者(1名中的1名)中发现了突变。在1例病例中,在患者被诊断为结直肠癌4年前,发现流出物中携带一个突变的K-ras等位基因。
(a)流出物样本含有足够的DNA,可用富集PCR检测。与结肠镜检查通常分析的局部区域不同,此类样本很可能总体上代表整个结肠。(b)在有患结直肠癌风险的患者常规获取的结肠冲洗液中可鉴定出K-ras基因突变。炎症性肠病患者和结肠镜检查正常的患者未出现此类突变。检测结肠冲洗液中的K-ras突变可能有助于识别可能患结肠癌风险较高的患者。
检查结肠流出物的能力提供了一种强大且便捷的采样来源,可能适用于未来的大规模筛查。